Immuneering Corp. Files 8-K on Shareholder Vote Matters
Ticker: IMRX · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: IMRX
TL;DR
IMRX filed an 8-K for a shareholder vote. Keep an eye on the outcome.
AI Summary
Immuneering Corp. filed an 8-K on June 13, 2024, reporting on matters submitted to a vote of security holders as of June 12, 2024. The filing details the company's corporate information, including its address in Cambridge, MA, and its fiscal year end of December 31st.
Why It Matters
This filing indicates that Immuneering Corporation held a vote of its security holders, which could pertain to significant corporate decisions or governance changes.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial distress or major operational changes.
Key Players & Entities
- Immuneering Corp. (company) — Registrant
- June 12, 2024 (date) — Date of earliest event reported
- June 13, 2024 (date) — Date of report
- 245 Main St. Second Floor Cambridge , MA 02142 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of Immuneering Corp.'s security holders?
The filing does not specify the exact matters voted upon, only that "Submission of Matters to a Vote of Security Holders" is the item information reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 12, 2024.
What is Immuneering Corp.'s principal executive office address?
Immuneering Corp.'s principal executive offices are located at 245 Main St. Second Floor Cambridge, MA 02142.
What is Immuneering Corp.'s fiscal year end?
Immuneering Corp.'s fiscal year ends on December 31st.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-13 16:09:51
Key Financial Figures
- $0.001 — stered Class A common stock, par value $0.001 per share IMRX The Nasdaq Global Market
Filing Documents
- imrx-20240612.htm (8-K) — 29KB
- 0001790340-24-000060.txt ( ) — 157KB
- imrx-20240612.xsd (EX-101.SCH) — 2KB
- imrx-20240612_lab.xml (EX-101.LAB) — 23KB
- imrx-20240612_pre.xml (EX-101.PRE) — 13KB
- imrx-20240612_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On June 12, 2024, Immuneering Corporation (the "Company") held its Annual Meeting of Stockholders. A total of 20,606,257 shares of the Company's Class A common stock were present in person or represented by proxy at the meeting, representing approximately 69.5 percent of the Company's outstanding Class A common stock as of the April 18, 2024 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 23, 2024. Item 1 — Election of two Class III directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. Votes Votes Broker Non- NOMINEE Votes FOR AGAINST WITHHELD Votes Robert J. Carpenter 11,180,033 0 3,731,579 5,694,645 Benjamin J. Zeskind 14,395,855 0 515,757 5,694,645 Item 2 — Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. Votes Votes FOR Votes AGAINST ABSTAINED Broker Non-Votes 20,337,444 38,268 230,545 0 Based on the foregoing votes, Robert J. Carpenter and Benjamin J. Zeskind were elected as Class III directors and Item 2 was approved.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNEERING CORPORATION Date: June 13, 2024 By: /s/ Michael D. Bookman Name: Michael D. Bookman Title: Chief Legal Officer and Secretary